Sulfite Oxidase Is a Novel Prognostic Biomarker of Advanced Gastric Cancer.


Journal

In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809

Informations de publication

Date de publication:
Historique:
received: 03 09 2020
revised: 20 10 2020
accepted: 21 10 2020
entrez: 6 1 2021
pubmed: 7 1 2021
medline: 22 6 2021
Statut: ppublish

Résumé

Sulfite oxidase (SUOX) is an enzyme present in the mitochondria, which has been demonstrated to be correlated with various malignant tumours. We evaluated SUOX expression in tissues of 98 cases of advanced gastric cancer and performed a clinicopathological assessment for metrics. Among 98 cases, 55 cases were classified into the SUOX low expression group, and 43 cases into the SUOX high expression group. There were more pStage IV cases in the low expression group. The median overall survival of the low expression group was shorter than that of the high expression group (p=0.020). In univariate and multivariate analysis, SUOX low expression level (p=0.039) and pStage (p<0.001) were independent prognostic factors. SUOX is an independent prognostic factor. Therefore, SUOX expression could also serve as a useful marker for elucidating the mechanism of gastric cancer proliferation and progression.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Sulfite oxidase (SUOX) is an enzyme present in the mitochondria, which has been demonstrated to be correlated with various malignant tumours.
MATERIALS AND METHODS METHODS
We evaluated SUOX expression in tissues of 98 cases of advanced gastric cancer and performed a clinicopathological assessment for metrics.
RESULTS RESULTS
Among 98 cases, 55 cases were classified into the SUOX low expression group, and 43 cases into the SUOX high expression group. There were more pStage IV cases in the low expression group. The median overall survival of the low expression group was shorter than that of the high expression group (p=0.020). In univariate and multivariate analysis, SUOX low expression level (p=0.039) and pStage (p<0.001) were independent prognostic factors.
CONCLUSION CONCLUSIONS
SUOX is an independent prognostic factor. Therefore, SUOX expression could also serve as a useful marker for elucidating the mechanism of gastric cancer proliferation and progression.

Identifiants

pubmed: 33402469
pii: 35/1/229
doi: 10.21873/invivo.12251
pmc: PMC7880800
doi:

Substances chimiques

Biomarkers 0
Biomarkers, Tumor 0
Sulfite Oxidase EC 1.8.3.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

229-237

Informations de copyright

Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

Science. 2006 Jun 16;312(5780):1650-3
pubmed: 16728594
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Med Mol Morphol. 2019 Sep;52(3):164-172
pubmed: 30631948
Med Mol Morphol. 2018 Jun;51(2):102-110
pubmed: 29280012
Clin Cancer Res. 2017 Mar 15;23(6):1586-1597
pubmed: 27620279
Surg Today. 2011 Jan;41(1):24-38
pubmed: 21191688
Cancer Res. 2009 Jun 1;69(11):4918-25
pubmed: 19458066
J Hepatol. 2013 Sep;59(3):510-7
pubmed: 23665285
Gan. 1968 Jun;59(3):251-8
pubmed: 5726267
J Gastroenterol Hepatol. 2010 Mar;25(3):479-86
pubmed: 20370726
Gastroenterology. 2016 May;150(5):1113-1124.e5
pubmed: 26836587
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
World J Gastroenterol. 2016 Feb 14;22(6):2046-59
pubmed: 26877609
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6394-8
pubmed: 9600976
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Drug Resist Updat. 2018 May;38:1-11
pubmed: 29857814
World J Gastroenterol. 2012 Oct 14;18(38):5470-5
pubmed: 23082065
Oncotarget. 2017 Jul 25;8(30):50273-50283
pubmed: 28488584
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer. 1992 Sep 1;70(5):1030-7
pubmed: 1515980
Mol Cancer. 2016 May 04;15(1):32
pubmed: 27145964
World J Surg. 1995 Jul-Aug;19(4):496-500
pubmed: 7676690
J Gastrointest Oncol. 2017 Feb;8(1):148-163
pubmed: 28280619
Nat Rev Dis Primers. 2017 Jun 01;3:17036
pubmed: 28569272

Auteurs

Yuta Yano (Y)

Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan.

Jun Akiba (J)

Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan; akiba@med.kurume-u.ac.jp.

Yoshiki Naito (Y)

Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan.

Eiji Sadashima (E)

Life Science Research Institute, Saga-ken Medical Centre Koseikan, Saga, Japan.

Haruhiko Cho (H)

Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.

Tsunekazu Hishima (T)

Department of Pathology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.

Hirohisa Yano (H)

Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH